Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
about
Current advancements and potential strategies in the development of MERS-CoV vaccinesCrystal structure-based exploration of the important role of Arg106 in the RNA-binding domain of human coronavirus OC43 nucleocapsid proteinStructural Basis for the Identification of the N-Terminal Domain of Coronavirus Nucleocapsid Protein as an Antiviral TargetThe adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primatesYeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.Receptor-binding domain as a target for developing SARS vaccines.Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityThe spike protein of SARS-CoV--a target for vaccine and therapeutic development.Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.Elucidation of the stability and functional regions of the human coronavirus OC43 nucleocapsid protein.AAV Vectors Vaccines Against Infectious Diseases.Oligomerization of the carboxyl terminal domain of the human coronavirus 229E nucleocapsid protein.Antigen fusion with C3d3 augments or inhibits humoral immunity to AAV genetic vaccines in a transgene-dependent manner.
P2860
Q27012578-E5BBD14F-3778-4D92-BF72-C92E23B04AF6Q27676849-A44CC6CF-5A33-458C-9302-7075341CE45DQ27681874-2E6A1C72-0E3B-4E66-BCB7-D3EE065FF9D6Q28729899-A4DD8F9E-DD79-4DDE-8BBA-FA90F449B9EEQ30218075-3A7A93F6-2C06-47FE-876B-2C433173B24CQ30353170-A4A6A2D9-4CFF-4E36-B23A-D35799C4B4C6Q30359335-263C707E-943F-4B54-BB9A-A6444236CD5EQ33904997-6B31BE48-EC8F-405C-9544-3E3624B3E229Q34015988-A96E3014-9C9A-4717-81B7-988D852DF86DQ34332142-05283D67-1225-4809-B9BD-DCEC464E964BQ34457808-A9A38DA2-3018-40FA-8B23-2689E6841F17Q35887626-C20A592B-FF29-4615-A724-92797D15B880Q36779713-0763768B-1CB2-48FD-8EEC-78B35232BDF4Q37183997-9D253A59-5545-4A57-9EE8-30ED9777FB31Q37361159-9D330FE7-37C1-471E-945C-CAE7854E814DQ37366744-4F133AB9-D4B3-4239-B8AA-AFB927C11F37Q37457784-F92DDADF-3F34-4530-BC48-73A0E1BF15C0Q37498000-FA8652FC-CA6E-4CD4-A17F-E80B1C62E804Q39239315-F3CEF739-6262-4A15-8AD5-5AEFC90EA1ABQ39771124-E37E748C-8442-4884-BCBD-3E7BF58605E4
P2860
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Priming with rAAV encoding RBD ...... es against SARS-CoV infection.
@en
Priming with rAAV encoding RBD ...... es against SARS-CoV infection.
@nl
type
label
Priming with rAAV encoding RBD ...... es against SARS-CoV infection.
@en
Priming with rAAV encoding RBD ...... es against SARS-CoV infection.
@nl
prefLabel
Priming with rAAV encoding RBD ...... es against SARS-CoV infection.
@en
Priming with rAAV encoding RBD ...... es against SARS-CoV infection.
@nl
P2093
P2860
P50
P1433
P1476
Priming with rAAV encoding RBD ...... ses against SARS-CoV infection
@en
P2093
Bo-Jian Zheng
Changyou Wu
Chris Chan
Dong-Yan Jin
Guangyu Zhao
Yongping Lin
Yusen Zhou
P2860
P304
P356
10.1016/J.VACCINE.2008.01.025
P407
P577
2008-02-04T00:00:00Z